{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:14:51Z","timestamp":1793146491677,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ekir.2023.08.036","type":"journal-article","created":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T05:13:47Z","timestamp":1693718027000},"page":"2254-2264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Randomized Trial Comparing SGLT2 Inhibition and Hydrochlorothiazide on Sympathetic Traffic in Type 2 Diabetes"],"prefix":"10.1016","volume":"8","author":[{"given":"Karsten","family":"Heusser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Tank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Diedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.08.036_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.08.036_bib2","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.08.036_bib3","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.08.036_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.08.036_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2023.08.036_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ekir.2023.08.036_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/HYPERTENSIONAHA.119.12885","article-title":"Sympathetic neural overdrive in the obese and overweight state: meta-analysis of published studies","volume":"74","author":"Grassi","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2023.08.036_bib8","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/HJH.0000000000002093","article-title":"Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis","volume":"37","author":"Grassi","year":"2019","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ekir.2023.08.036_bib9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/HJH.0000000000002431","article-title":"Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"38","author":"Grassi","year":"2020","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ekir.2023.08.036_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/HYPERTENSIONAHA.108.119883","article-title":"Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives","volume":"54","author":"Grassi","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2023.08.036_bib11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/HJH.0000000000002760","article-title":"Elevated heart rate and cardiovascular risk in hypertension","volume":"39","author":"Mancia","year":"2021","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ekir.2023.08.036_bib12","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.ekir.2023.08.036_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ekir.2023.08.036_bib14","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2023.08.036_bib15","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2023.08.036_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2023.08.036_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2023.08.036_bib18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.ekir.2023.08.036_bib19","article-title":"Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure","volume":"10","author":"Hamaoka","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2023.08.036_bib20","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.ekir.2023.08.036_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.clpt.2006.02.002","article-title":"Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects","volume":"79","author":"Heusser","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2023.08.036_bib22","doi-asserted-by":"crossref","first-page":"H645","DOI":"10.1152\/ajpheart.00535.2001","article-title":"Hypovolemia and neurovascular control during orthostatic stress","volume":"282","author":"Kimmerly","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ekir.2023.08.036_bib23","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1038\/s41598-019-40343-w","article-title":"Ultrafine particles and ozone perturb norepinephrine clearance rather than centrally generated sympathetic activity in humans","volume":"9","author":"Heusser","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2023.08.036_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/00004872-200309000-00027","article-title":"Comparative effects of Candesartan and Hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study","volume":"21","author":"Grassi","year":"2003","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.ekir.2023.08.036_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049163","article-title":"Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature","volume":"7","author":"Alshurafa","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2023.08.036_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijsu.2011.10.001","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"10","author":"Moher","year":"2012","journal-title":"Int J Surg"},{"key":"10.1016\/j.ekir.2023.08.036_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00125-020-05145-0","article-title":"Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes","volume":"63","author":"Gueguen","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2023.08.036_bib28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/bph.15381","article-title":"Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation","volume":"178","author":"Yang","year":"2021","journal-title":"Brit J Pharmacol"},{"key":"10.1016\/j.ekir.2023.08.036_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2023.08.036_bib30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.24.5.1197","article-title":"Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension","volume":"24","author":"Gifford","year":"1961","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.08.036_bib31","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/dom.13855","article-title":"Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes","volume":"21","author":"Dekkers","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2023.08.036_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2023.08.036_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.112.193045","article-title":"Salt-induced hypertension in a mouse model of Liddle syndrome is mediated by epithelial sodium channels in the brain","volume":"60","author":"Van Huysse","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2023.08.036_bib34","doi-asserted-by":"crossref","first-page":"R1882","DOI":"10.1152\/ajpregu.90529.2008","article-title":"Afferent renal denervation impairs baroreflex control of efferent renal sympathetic nerve activity","volume":"295","author":"Kopp","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ekir.2023.08.036_bib35","doi-asserted-by":"crossref","first-page":"H974","DOI":"10.1152\/ajpheart.01090.2002","article-title":"Weight loss improves neurovascular and muscle metaboreflex control in obesity","volume":"285","author":"Trombetta","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ekir.2023.08.036_bib36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/01.HYP.18.6.783","article-title":"Effect of energy-restricted diet on sympathetic muscle nerve activity in obese women","volume":"18","author":"Andersson","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2023.08.036_bib37","doi-asserted-by":"crossref","first-page":"E503","DOI":"10.1210\/jc.2010-2204","article-title":"The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components","volume":"96","author":"Straznicky","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2023.08.036_bib38","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/01.CIR.97.20.2037","article-title":"Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans","volume":"97","author":"Grassi","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.08.036_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clnu.2018.01.006","article-title":"Effects of weight changes in the autonomic nervous system: a systematic review and meta-analysis","volume":"38","author":"Costa","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ekir.2023.08.036_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01826234","article-title":"Long-term variability and reproducibility of resting human muscle nerve sympathetic activity at rest, as reassessed after a decade","volume":"3","author":"Fagius","year":"1993","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ekir.2023.08.036_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0895-7061(03)00917-8","article-title":"Elevation of sympathetic activity by eprosartan in young male subjects","volume":"16","author":"Heusser","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ekir.2023.08.036_bib42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0022-510X(80)90099-4","article-title":"Sympathetic reflex latencies and conduction velocities in patients with polyneuropathy","volume":"47","author":"Fagius","year":"1980","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ekir.2023.08.036_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00260954","article-title":"Microneurographic findings in diabetic polyneuropathy with special reference to sympathetic nerve activity","volume":"23","author":"Fagius","year":"1982","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2023.08.036_bib44","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1113\/jphysiol.2013.261362","article-title":"Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors","volume":"591","author":"Okada","year":"2013","journal-title":"J\u00a0Physiol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923014730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923014730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:46:13Z","timestamp":1762832773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923014730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2468024923014730"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.08.036","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Trial Comparing SGLT2 Inhibition and Hydrochlorothiazide on Sympathetic Traffic in Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}